Opendata, web and dolomites

Nyxoah

Ultra-small implanted neurostimulation device for the treatment of Obstructive Sleep Apnea

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 Nyxoah project word cloud

Explore the words cloud of the Nyxoah project. It provides you a very rough idea of what is the project "Nyxoah" about.

implantations    neurostimulation    annual    tissue    outcome    plan    cardiac    drawbacks    50    disposable    tiny    regualatory    obese    resistance    lifelong    100m    security    line    daytime    ineffective    fail    neurocognitive    2009    performance    powered    burnout    central    disruptive    risk    disorder    patients    poor    mask    worldwide    morbidity    public    treatment    health    monitoring    unpleasant    feedback    compliance    invasive    chip    company    responds    attached    synced    options    industrialization    mortality    first    cardiovascular    device    closed    sleepiness    surgery    outright    implanted    efficacy    disease    infection    cohorts    elderly    150b    communicates    clinical    trials    lower    reimbursement    displays    linked    nyxoah    people    stroke    social    healthcare    economic    machine    acute    detects    tells    cpap    stuck    constant    patient    standards    noisy    refuse    keep    activation    prevalent    chronic    neurostimulator    smart    smaller    wirelessly    uncomfortable    continue    cloud    depression    chin    physicians    pulse    founded    impacts    apnea    attack    obstructive    sleep    loop    pressure    adjust    world    patch    therapeutic    nerve    implant    arrhythmia    heart    agencies    app   

Project "Nyxoah" data sheet

The following table provides information about the project.

Coordinator
NYXOAH SA 

Organization address
address: RUE DU FOND CATTELAIN 2
city: MONT-SAINT-GUIBERT
postcode: 1435
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Belgium [BE]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.4. (Active ageing and self-management of health)
2. H2020-EU.2.1.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Information and Communication Technologies (ICT))
3. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
4. H2020-EU.3.1.6. (Health care provision and integrated care)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2016
 Duration (year-month-day) from 2016-06-01   to  2016-09-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    NYXOAH SA BE (MONT-SAINT-GUIBERT) coordinator 50˙000.00

Map

 Project objective

Obstructive Sleep Apnea is the world's most common sleep disorder and affects 100m people worldwide. It is particularly prevalent among elderly and obese cohorts and is a lifelong disease, with acute and chronic health impacts. It is linked to increased cardiovascular morbidity and mortality, and associated with increased risk of heart attack, cardiac arrhythmia, stroke, daytime sleepiness, depression and poor neurocognitive performance. Estimated annual economic costs of the disease are €60-150b. Established therapeutic options are uncomfortable with unpleasant side effects and/or ineffective; they can also require invasive surgery. Compliance is a major problem with the first line treatment, CPAP: 50% of users refuse it outright or fail to continue use after 1 year. Nyxoah's disruptive neurostimulation device responds directly to these needs and drawbacks. Central to the system is a tiny device implanted under the chin that - compared to other neurostimulator implantations - is smaller, less invasive and has lower risk of infection. The device is powered wirelessly by an activation chip, which is attached to a disposable smart patch and stuck under the chin before sleep. No mask, no noisy machine, no unpleasant side effects. The chip has a closed feedback loop with the implant, which detects tissue resistance and tells the chip to adjust the pulse to keep constant pressure on the nerve, to avoid burnout; it also communicates wirelessly with an app, which displays useful information (synced with the cloud) for use by patients, physicians and social security agencies; this is a key development to allow treatment compliance monitoring and therefore for reimbursement. During the Phase 1 project, the company, founded in 2009, will assess scale-up industrialization plan, product development according to regualatory standards and clinical trials to be deployed in Europe to show the system efficacy on patient outcome and public healthcare costs.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "NYXOAH" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "NYXOAH" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.4.;H2020-EU.2.1.1.;H2020-EU.2.3.1.;H2020-EU.3.1.6.)

CLINICOVERY (2018)

CLINICOVERY, a versatile, high quality, environmental-friendly, easy to use e-Clinical solution for clinical research

Read More  

SensUS (2018)

SensUS: A non-invasive and quantitative ultrasound (QUS) device for an objective monitoring of the childbirth labour process.

Read More  

ClearRing (2018)

An innovative, minimally invasive medical device used for treatment of Benign Prostatic Hyperplasia symptoms.

Read More